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Abstract
Background: Herpes simplex virus type-2 (HSV-2) infection enhances the transmission and acquisition of human
immunodeficiency virus (HIV). This occurs in symptomatic and asymptomatic stages of HSV-2 infection, suggesting that
obvious herpetic lesions are not required to increase HIV spread. An animal model to investigate the underlying causes of
the synergistic action of the two viruses and where preventative strategies can be tested under such complex physiological
conditions is currently unavailable.
Methodology/Principal Findings: We set out to establish a rhesus macaque model in which HSV-2 infection increases the
susceptibility to vaginal infection with a model immunodeficiency virus (simian-human immunodeficiency virus, SHIV-RT),
and to more stringently test promising microbicides. HSV-2 exposure significantly increased the frequency of vaginal SHIV-
RT infection (n=6). Although cervical lesions were detected in only ,10% of the animals, long term HSV-2 DNA shedding
was detected (in 50% of animals followed for 2 years). Vaginal HSV-2 exposure elicited local cytokine/chemokine (n=12)
and systemic low-level HSV-2-specific adaptive responses in all animals (n=8), involving CD4
+ and CD8
+ HSV-specific T cells
(n=5). Local cytokine/chemokine responses were lower in co-infected animals, while simian immunodeficiency virus (SIV)-
specific adaptive responses were comparable in naı ¨ve and HSV-2-infected animals (n=6). Despite the increased frequency
of SHIV-RT infection, a new generation microbicide gel, comprised of CarraguardH and a non-nucleoside reverse
transcriptase inhibitor MIV-150 (PC-817), blocked vaginal SHIV-RT infection in HSV-2-exposed animals (n=8), just as in naı ¨ve
animals.
Conclusions/Significance: We established a unique HSV-2 macaque model that will likely facilitate research to define how
HSV-2 increases HIV transmission, and enable more rigorous evaluation of candidate anti-viral approaches in vivo.
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Introduction
Herpes simplex virus type-2 (HSV-2) prevalence is between 19–
50% in adults worldwide [1,2] and increases the risk of human
immunodeficiency virus (HIV) acquisition by ,3 fold [3,4]. HSV-
2 infection is characterized by viral shedding at mucosal surfaces,
occurring in the presence of lesions (clinical reactivation) or with
very mild or no symptoms (subclinical reactivation). HIV
acquisition risk is increased during both the symptomatic and
asymptomatic phases of genital herpes. Individuals with recently
acquired HSV-2 infection showed a higher incidence of HIV
acquisition (22.6% per 100 person-years) compared to chronically
infected people (7.5% per 100 person-years) [5]. These findings
correlate with the observation that, although HSV-2 results in a
chronic infection, the frequency of symptomatic genital herpes
reactivation decreases with time since infection [6].
Primary and recurrent genital HSV-2 infection involves
disruption of the epithelial surface. The interaction between
HSV-2 and epithelial cells triggers cytokine and chemokine
secretion [7] to recruit dendritic cells (DCs), macrophages, and
CD4
+ and CD8
+ T cells to control infection and symptomatic
reactivation [8–11]. HSV-specific CD8
+ T cells have been
documented at the dermal-epidermal junction next to peripheral
sensory nerve endings in HSV-infected people, suggesting that
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e8060virus reactivation occurs more frequently than first thought [8].
Reactivated shedding and lesions were shown to be rapidly cleared
(within a median ,12 h) and predominantly asymptomatic
(,10% with lesions) [12]. Longer reactivation periods were
associated with a higher viral loads and frequency of lesions
(,30% when shedding lasted longer than 24 h). The rapid
clearance of virus is likely due to the persistence of the CD8
+ T
cells within the tissues, which are able to clear the subclinical
HSV-2 reactivation [8].
HSV-2-activated CD4
+ T cells can act as target cells for HIV,
facilitating HIV acquisition. HSV-2 and HIV can also co-infect
lymphocytes [13] and macrophages [14] in vitro, resulting in the
up-regulation of HIV replication. While epithelial cells are the
major targets for HSV-2 infection, human [15,16] and macaque
[17] DCs are susceptible to HSV-2 infection in vitro resulting in the
down-modulation of their immunostimulatory functions. Notably,
HSV-2-infected DCs stimulate weaker SIV-specific responses than
uninfected DCs [17]. Thus, the presence of more immature DCs
with suboptimal function would provide even more targets to
support HIV replication in the absence of maximal immune
activity. The notion that increased HIV infection can occur as a
result of immune dysfunction caused by HSV-2 infection is
supported by the fact that HSV-2-infected people lacking obvious
lesions exhibit increased susceptibility to HIV [18,19]. Addition-
ally, the observation that treating HSV-2 infection with acyclovir
did not affect the incidence of HIV acquisition [20], suggests that
immune damage might already have occurred, and is not reversed
by anti-HSV treatment. However, there is increasing evidence for
subclinical reactivation of HSV-2 (90% in women and 80% in
men), which is associated with microscopic lesions that contain
activated CD4
+ T cells (reviewed in [2]). Moreover, a recent
report from Zhu et al revealed that cellular infiltrates at the site of
HSV-2 reactivation comprised CD4
+ and CD8
+ T cells, as well as
myeloid and plasmacytoid DCs (MDCs and PDCs), all of which
persisted for months after the lesions healed, even with daily
antiviral therapy [21]. The persistence of these potential HIV
targets helps explain why anti-HSV therapy did not reduce HIV
acquisition. Treatment of HSV infection has been shown to
reduce the levels of HIV in plasma and mucosal fluids in HSV/
HIV-infected men and women [22–24], probably by reducing the
HSV-mediated activation of CD4
+ T cells thereby lowering HIV
production.
To further understand how HSV-2 infection increases HIV
spread, and to more accurately test novel anti-viral approaches, a
macaque mucosal HSV-2 infection model was developed. HSV-2
exposure resulted in long term HSV-2 DNA shedding, increased
frequency of vaginal SHIV-RT infection, and elicited local and
systemic responses. The efficacy of a microbicide under the
physiological complexity of a co-infection vs SHIV-RT challenge
alone was also demonstrated. Such a model is of fundamental
importance to better understand the interplay of HSV-2 and HIV,
and provides a useful means of testing the efficacy of preventative
and therapeutic strategies.
Methods
Animals and Treatments
Adult female Chinese rhesus macaques (Macaca mulatta) were
housed at the Tulane National Primate Research Center
(TNPRC). Herpes B virus is prevalent in most macaque colonies
[25,26]. To limit the chance that prior infection with Herpes B
virus might impact the susceptibility to HSV-2 infection, all
animals used in these studies were prescreened for Herpes B virus
infection and only Herpes B virus negative animals were used.
Animals were injected with 30 mg of Depo-Provera i.m. and 5
weeks later intra-vaginally (i.vag.) challenged with 2610
8 plaque
forming units (pfu) HSV-2 strain G (American Type Culture
Collection, ATCC, Manassas, VA) in 1 ml of serum-free RPMI
1640 (Cellgro/Mediatech, Manassas, VA). Animals were Depo-
Provera treated again (1.5–7 months after HSV-2 challenge),
before being co-challenged i.vag. with 2610
8 pfu HSV-2 and 200
or 10
3 TCID50 SHIV-RT (genomic backbone SIVmac239 with the
RT gene of HIV-1) [27] in 1 ml of serum-free RPMI 1640. An
additional 4 animals were challenged with HSV-2 intra-rectally
(i.r.) before being Depo-Provera-treated (,8–11 months after the
primary HSV-2 challenge) and i.vag. co-challenged as above. A
schematic describing the various challenge groups is provided in
Figure S1. Control groups included SHIV-RT challenged animals
receiving a single Depo-Provera treatment or a double Depo-
Provera treatment (given within 3 months of each other in the
absence of HSV-2). In later studies, 3 ml of the microbicide
candidate gel (or placebo) was applied 30 minutes or 24 hours
prior to application of 1 ml of virus [28]. Animals remained in a
supine position for 20 minutes post-challenge, to allow absorption
of virus. All animals and their respective treatments are
summarized in Tables 1 and 2.
HSV-2/SHIV-RT and SHIV-RT-infected monkeys were
treated with the mouse-human chimeric anti-CD8 mAb cM-
T807 (NIH Nonhuman Primate Reagent Resource-Beth Israel
Deaconess Medical Center, Boston, MA). The animals received
10 mg/ml s.c. at day 0, followed by 5 mg/kg i.v. on days 3, 7, and
10 as described in the published protocol [29].
Blood and mucosal fluid samples were collected as indicated.
Vaginal and cervical pinch biopsies were collected 3–12 months
post-HSV-2/SHIV-RT co-challenge. Biopsy procedures were
followed with buprenorphine 0.01 mg/kg for analgesia. During
all procedures monkeys were anesthetized with tiletimine/
zolazepam (8 mg/kg). Blood samples for hematological analysis,
immunological and virological assays were taken in the morning
prior to feeding. Protocols were reviewed and approved by the
Institutional Animal Care and Use Committee of TNPRC.
Animal care procedures were in compliance with the regulations
detailed under the Animal Welfare Act [30] and in the Guide for
the Care and use of Laboratory Animals [31]. Animals that did
not become infected with SHIV-RT (verified by negative plasma
viremia and lack on adaptive immunity to SIV) were recycled and
re-challenged as indicated.
Virus Stocks
The generation of HSV-2 strain G stocks was performed on
Vero cells (CCL-81; ATCC) [32] and virus titers were determined
by plaque-forming assay [32]. Aliquots of HSV-2 (and the no
virus-containing supernatant controls) were UV-inactivated as
previously described [17]. Aliquots of infectious and UV-
inactivated virus were stored at 280uC until use. SHIV-RT
stocks were grown in PHA-activated human PBMCs (kindly
provided by Disa Bo ¨ttiger, Medivir AB, Sweden). Stocks were re-
titered using the 174XCEM cell line (NIH AIDS Research &
Reference Reagent Program) and the TCID50 was calculated
using the Reed and Muench formula.
Microbicide Preparation
PC-817 (Lot numbers: 100907, 101606-A, 011508, 032707-A)
is 3% (w/v) CarraguardH containing 500 mM of the non
nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150
(Medivir AB, Sweden) [28]. 2.5% (25 mg/ml) methyl cellulose
(MC) (Lot numbers: 100207, 101806-A, 032807, 011008) (Fisher,
HSV-2 Increases SHIV Infection
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room temperature and used within 7–10 days of preparation.
Cell Isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from
EDTA blood using Ficoll-Hypaque density gradient centrifugation
(Amersham Pharmacia Biotech, Uppsala, Sweden). Axillary,
inguinal and mesenteric lymph nodes (LNs), as well as vaginal
and cervical tissues were obtained at necropsy. Pooled LN cell
suspensions were prepared as we described previously [33].
Mucosal cell suspensions were prepared by incubating the tissues
with 200 mg/ml gentamycin (Invitrogen/GIBCO, Carlsbad, CA)
in RPMI 1640 (Cellgro/Mediatech, Manassas, VA) 10% FBS
(Cellgro/Mediatech) for 1–2 hours, and after 2 washes in PBS 1x
Table 1. HSV-2 exposure increases SHIV-RT infection frequency.
HSV-2 status SHIV-RT TCID50 No. of Depo-Provera Treatments# Animal No. SHIV-RT-specific
Infection IFNc Ab
Naı ¨ve ,200 1X GF15 2 2 2
GF16 2 2 2
GJ28 2 2 2
GJ29 2 2 2
GF13 2 2 2
1000 1X FI80 + + +
FI81 + + +
FI82 + + +
DE38 2 + 2
GF15 2 2 2
GF16 2 2 2/+
GJ43 + + +
GJ51 + + +
GK06 2 2 2
GK05 2 2 2
GJ28 + + +
GJ29 2 2 2
GF13 2 2 2
Infected 200 1X GF24 2 2 2
GJ82 + + +
DT72 + + +
CR03 2 2 2
GF11
b + + +
GF04
b 2 2 2
GF10
b 2 2 2
GF19
b 2 2 NA
1000 1X GF24 + + +
GF22 + + +
GF09 + + +
GF10
a + + NA
GF19
a + 2 NA
GF04
a + + NA
Naı ¨ve 1000 2X GK06 + + +
GK03 + 2 +
GJ90 + + +
GJ91 + + +
Infected 1000 2X GJ42 + + +
GJ81 + + +
#Number of Depo-Provera treatments within a 3 month window.
aindicates intra rectal (i.r.) route of HSV-2 infection.
NA, sample not available.
Note, some uninfected animals were recycled and rechallenged and, therefore are listed more than once.
doi:10.1371/journal.pone.0008060.t001
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imately 2 mm) and incubated in 0.1 mg/ml Collagenase/Dispase
(Roche Diagnostic Corporation, Indianapolis, IN) in RPMI 1640
(Cellgro/Mediatech) 10% FBS (Cellgro/Mediatech), containing
1 mg/ml Hyaluronidase (400–1000 U/ml) (Sigma), 0.5 mg/ml
Collagenase II (Sigma) 1 mg/ml DNase I (Roche Diagnostic
Corporation), at 37uC for 20 minutes, shaking. The suspension
was passed through a metal sieve, the larger pieces of tissue being
disrupted further using a sterile glass pestle. The tissue that was not
completely disrupted was re-suspended in the medium and the
procedure above was followed, for a maximum of 3 times. The
final cell suspension was filtered through a 70 mm nylon cell
strainer (BD-Falcon, Franklin Lakes, NJ) and washed twice with
medium. Mucosal cells were stored as dry pellets for PCR.
IFN-c ELISPOT
The numbers of IFN-c spot-forming cells (SFCs) in the blood
and LN preparations were measured by ELISPOT [34]. Cells
were cultured in triplicate (100 ml), in plates coated with anti-IFN-
c Abs (clone MD-1; Biosource International, Camarillo, CA) in
the presence of UV-inactivated HSV-2 (5 pfu equivalents/cell),
aldrithiol 2 (AT-2)-inactivated SIVmneE11s (300 ng/ml p27; AT-
2 SIV lot # P4055), their respective no-virus microvesicle (MV)
controls generated from the same cells used to generate the viral
stocks (AT-2 SIV MV control lot # P3856) and 1 mg/ml ConA
(Sigma) (to control for cell functionality and assay integrity). After
overnight incubation at 37uC cells were lysed and the plate
developed as described [35]. Spots were counted using an AID
ELISPOT reader (Cell Technology, Columbia, MD). The SIV-
and HSV-2-specific IFN-c responses were calculated subtracting
any background responses to the respective no-virus MV controls.
Culture medium used throughout was RPMI 1640 (Cellgro/
Mediatech), containing 2 mM L-glutamine (Invitrogen/GIBCO)
10 mM HEPES (N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic
acid) (Invitrogen/GIBCO), 50 mM 2-mercaptoethanol (Sigma)
penicillin (100 U/ml) and streptomycin (100 mg/ml) (Invitrogen/
GIBCO) and 1% heparinized human plasma (Innovative
Research, Southfield, MI).
Vaginal Fluid Collection
Vaginal swabs were obtained by inserting foam swabs into the
vaginal cavity for 5 minutes and immersing them in 1 ml of sterile
PBS containing 1% FCS (Cellgro/Mediatech) and penicillin-
streptomycin. Samples were kept at 4uC prior to processing (within
Table 2. 30 minute pretreatment with PC-817 prevents vaginal SHIV-RT infection in HSV-2-infected macaques.
Gel
Time of gel administration
before challenge SHIV-RT TCID50 Animal No. SHIV-RT-specific
Infection IFNc Ab
MC 30 min/24 h 1000 GF24 + + +
GF22 + + +
GF09 + + +
GJ42 + + +
GJ81 + + +
PC-817 30 min 1000 GF24 2 2 2
GF26 2 2 2
GF28 2 2 2
GF31 2 2 2
GJ82 2 2 2
GJ83 2 2 2
GJ94 2 2 2
GJ98 2 2 2
PC-817 24 h 1000 GF26 + + 2
GF28 + + +
GJ83 + + 2
GJ94 + + 2
GJ98 + + +
MC 24 h 200 GF24 2 2 2
GJ82 + + +
PC-817 24 h 200 GF26 2 2 2
GF28 2 2 2
GF31 + + +
GJ83 2 2 2
GJ94 2 2 2
GJ98 2 2 2
SHIV-RT negative animals (no viral RNA in plasma and no adaptive immunity) were recycled and re-challenged as indicated.
NA, sample not available.
doi:10.1371/journal.pone.0008060.t002
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remaining samples were centrifuged at 3500 rpm for 10 minutes.
Total fluids or aliquots of supernatants and the pelleted cells were
stored at 280uC.
Cytokine and Chemokine Analysis
Stored vaginal swab fluid was thawed and centrifuged at
3000 rpm for 10 minutes. Supernatants were then analyzed using
the monkey-reactive Beadlyte human 14-plex Detection System
according to the manufacturer’s instructions (Upstate Biotechnol-
ogy, Lake Placid, NY). The system recognizes macaque IL1b, IL2,
IL3, IL4, IL5, IL6, IL12p40, CXCL8, IFNc, TNFa, GM-CSF,
CCL2, CCL3 and CCL5. Samples were analyzed using Luminex
100 or Luminex 200 (Luminex, Austin, TX) and StarStation
software (Applied Cytometry Systems, Sacramento, CA).
Flow Cytometry
A standard 4-color flow cytometry analysis was performed to
examine the DCs present in macaque blood and LNs using Abs
and conditions reported previously [33]. To analyze CD8
+ T cell
counts in blood of CD8
+-depleted animals 3-color TruCount flow
cytometry was used. Whole blood was stained according to the
manufacturer’s instruction for phycoerythrin (PE)-conjugated anti-
CD8 (clone DK25; BD Pharmingen), fluorescein isothiocyanate
(FITC)-conjugated anti-CD4 (clone L200; Dako), peridinin-
chlorophyll-Cychrome (PerCP-Cy5.5)-conjugated anti-CD3 (clone
SP34; BD Pharmingen). Samples were acquired using a
FACSCalibur flow cytometer (BD Immunocytometry Systems,
CA) and analyzed using FlowJo software (Tree Star, CA).
Intracellular cytokine staining (ICS) was used to detect antigen-
specific T cells using minor modifications of a previously described
protocol [36]. 5610
6 PBMCs were incubated for 6 hours at 37uC
with UV-inactivated HSV-2 (5 pfu equivalents/cell), AT-2 SIV
(300 ng/ml p27, lot # P4055), their respective MV controls, or
50 nM phorbol 12-myristate 13-acetate (PMA) and 1 mg/ml
ionomycin (both Sigma, St. Louis, MO). The cells were stimulated
in a total volume of 1 ml of RPMI 1640, containing 2 mM L-
glutamine, 10 mM HEPES, 50 mM 2-mercaptoethanol, penicillin
(100 U/ml) and streptomycin (100 mg/ml) and 10% heat-
inactivated fetal calf serum (Cellgro/Mediatech) in 24-well plates
(BD Falcon) pre-coated with anti-CD28 and anti-CD49d co-
stimulatory Abs (both 10 mg/ml BD Pharmingen) cross-linked by
2.5 mg/ml GAM IgG F(ab)2 (KPL, Gaithersburg, MD) (for the
antigen-specific responses). Brefeldin A (Sigma) was added to the
cultures at 10 mg/ml for the final 4.5 hours of incubation.
Stimulated cells were surface stained with PerCP-Cy5.5-conjugat-
ed anti-CD4 (clone SP34-2, BD Biosciences) and Pacific Blue-
conjugated anti-CD3 Abs (clone L200, BD Biosciences), washed in
FACS Wash (5% FBS and 0.1% sodium azide in PBS) and fixed
overnight with 4% paraformaldehyde (Electron Microscopy
Sciences). After permeabilization for 20 minutes at 4uC using
FACS permeabilizing solution (BD Biosciences) cells were stained
with FITC-conjugated anti-TNFa (clone MAb11, Biolegend, San
Diego, CA), PE-conjugated anti-IL-2 (clone N7.48A) and APC-
conjugated anti-IFNc (clone 45-15, both Miltenyi, Auburn, CA)
Abs for 1 hour at room temperature in permeabilizing solution
followed by washing and fixation in FACS fixation solution (BD
Biosciences). Five hundred thousand events were collected gating
on lymphocytes (small, non granulated cells) on a BD LSRII (BD
Biosciences) and data were analyzed using FlowJo software.
HSV-2 DNA PCR
DNA was extracted from 200-600 ml aliquots of vaginal fluid, the
pelleted material obtained from fluids, and vaginal and cervical
biopsy samples using the QIAamp DNA blood Mini Kit (QIAGEN,
Valencia CA, USA) according to the manufacturer’s instructions
and eluted into 100 ml elution buffer. DNA was extracted from
vaginal and cervical biopsy tissues using ATL buffer and Proteinase
K (Qiagen), followed by extraction with the QIAamp DNA blood
Mini Kit as above. HSV-2 DNA shedding was determined by
measuring the presence of the HSV-2 UL30 gene (which encodes
the viral DNA polymerase) using a nested PCR. This assay was able
to reproducibly detect HSV-2 UL30 DNA signals from 0.5 infected
cells(singlereplicates)or0.0005infected cells(atleast2positivesin6
replicates; Fig. S2) within 45,000 uninfected cells. Sequencing
analysis confirmed that the 146 bp band detected was within the
HSV-2 UL30 gene.Theexternal primers used toamplifypart ofthe
HSV-2 UL30 gene were: Ext UL30 Fw (59- GCATCATC-
TACGGGGACACG) and Ext UL30 Rev (59- TCGGC-
GGTGAGGACAAAGTC). The internal UL30 primers used were:
UL30 Fw (59- GACACGGACTCCATTTTCGT), UL30 Rev (59-
AGCAGCTTGGTGAACGTTTT). The GAPDH gene was used
as positive assay control with primer sequences: GAPDH Fw (59-
GAAGGTGAAGGTCGGAGT), GAPDH Rev (59- GAA-
GATGGTGATGGGATTTC). Both external and nested PCR
assays were performed in a 20 ml reaction mixture containing
0.01 mM UL30 primers or 0.02 mM GAPDH primers, 4 mMo f
dNTPs (Invitrogen, Carlsbad Ca, USA), 0.4units of Hotstart Taq
DNA polymerase (Qiagen); the external reaction contained up to
200 ngofDNA.AftertheactivationoftheHotstartTaqpolymerase
at 95uC for 12 minutes, DNA was amplified by using the MyCycler,
Thermal Cycler (Bio-Rad, Laboratories, Inc., Hercules, CA) for 35
cycles, each at 95uC for 45 seconds, 58uC for 45 seconds, 72uC for
15 seconds, with a final extension at 72uC for 5 minutes. 1 ml of the
UL30 amplified product was used for a second amplification of 35
cycles with the internal UL30 primers. Amplified products were
detected by gel electrophoresis on 2% agarose gel, stained with
ethidium bromide and visualized with UV light.
SHIV-RT Plasma Load Detection
Plasma was separated from whole blood by centrifugation at
2000 rpm for 10 minutes, clarified at 2000 rpm for 10 minutes at
4uC and stored at 280uC in 1 ml aliquots. Virus loads were
determined by quantitative RT-PCR assay for SIV gag RNA [37].
Humoral Responses
Plasma samples obtained at the indicated times after infection
were monitored for the presence of SIV envelope Abs by using an
established ELISA protocol [38]. HSV-2 specific Abs were detected
by HerpeSelect 2 ELISA IgG (Focus Diagnostic, Cypress, CA).
Statistical Analyses
The Fisher’s exact test was used for statistical comparison of the
percentage of SHIV-RT infected animals in the different groups
(GraphPad Prism version 5.02 for Windows, GraphPad Software,
San Diego, CA). For all other pairwise comparisons, the semi-
parametric Conover-Iman t-test on the ranked data was used (SAS
9.2 for Windows, The SAS Institute, Cary, NC). For the paired
comparisons presented in Figure S3C, the Conover-Iman t-test on
the sign-ranked data was used. P values,0.05 were taken as
statistically significant.
Results
Long Term Shedding of HSV-2 DNA following Vaginal
HSV-2 Challenge
To study the impact of HSV-2 on immunodeficiency virus
infection, macaques were challenged with HSV-2 and later co-
HSV-2 Increases SHIV Infection
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used as a proof of concept to maximize the chance of establishing
HSV-2 infection and would model the human setting where
someone first encounters HSV-2 and then is coincidently exposed
to HSV-2 and HIV. Animals were Depo-Provera-treated in an
attempt to render them more uniformly susceptible to HSV-2 (as
seen for immunodeficiency virus infection [39]). Approximately
10% of the monkeys that were challenged i.vag. with HSV-2
developed cervical inflammation and/or lesions within 1 day of
challenge and these resolved within 7–10 days (data not shown).
Using a sensitive PCR assay to detect the HSV-2 UL30 gene (Fig.
S2), long term HSV-2 DNA shedding into the vaginal fluids was
demonstrated (Fig. 1). The input inoculum was detected in all
animals tested 1 day after challenge, followed by varying levels of
shedding over time (Fig. 1A; not all animals were tested at all time
points). Although the available animal numbers were lower at the
later time points, HSV-2 DNA was detected in 50% of the animals
tested approximately 2 years after the primary HSV-2 challenge.
More replicates of each sample (up to 6) were analyzed for the later
time points in order to detect low level infections (e.g., Fig. S2). No
HSV-2 DNA shedding was detected in one of the fifteen animals
tested (GF19, only tested on two occasions), while the shedding
frequency ranged from 20% to 100% in the remaining animals
(Fig. 1B).
In an attempt to reactivate and increase HSV-2 DNA shedding
as further proof of HSV-2 infection, cervical and vaginal pinch
biopsies (2–4 each) were taken from 8 animals approximately 3–6
(Biopsy 1) and 9–12 (Biopsy 2) months after HSV-2/SHIV-RT co-
challenge (once infected with SHIV-RT; approximately 15–24
months post primary HSV-2 exposure). The presence of HSV-2
DNA was monitored in the tissues (at biopsy) and in fluids (4 hours
to 7 days post biopsy) and a representative PCR result for the
fluids is shown in Figure 1C. After the first biopsy, HSV-2 DNA
was detected in the cervical tissues of 1 of the animals but not in
the vaginal tissues (data not shown), while HSV-2 DNA was
detected in the swabs of 25% of the animals 4 hours later and in
75% of the animals within the next days (Fig. 1D). Considerably
less shedding was seen after the second biopsy and, even after
performing the PCR on multiple replicates of each sample (to
increase our sensitivity of detection, Fig. S2), there was limited
increased shedding at this late time point (Fig. 1D, only 10–20% of
the animals showed any positivity by PCR). Thus, vaginal HSV-2
exposure of macaques resulted in long-term productive HSV-2
infection as evidenced by viral shedding for up to 2 years that
progressively reduced.
Vaginal HSV-2 Exposure Increases the Frequency of
SHIV-RT Infection
In order to determine if HSV-2-exposed macaques exhibited
increased susceptibility to immunodeficiency virus infection (like
humans), we co-challenged HSV-2-infected animals with HSV-2
and SHIV-RT. SHIV-RT, which expresses the reverse transcrip-
tase of HIV in the context of SIV, was chosen as our challenge
immunodeficiency virus since we intended to test the efficacy of a
new generation NNRTI-containing microbicide gel in HSV-2-
infected animals, which has been shown to be effective in HSV-2
naı ¨ve animals [28]. The initial SHIV-RT challenges (10
3 TCID50)
revealed that all HSV-2-exposed and naı ¨ve animals that received
two Depo-Provera treatments within 11 weeks prior to SHIV-RT
challenge became infected (Fig. 2A, 2X Depo). In these animals,
Figure 1. HSV-2 shedding after vaginal exposure. (A) Vaginal swabs were collected at the indicated times after HSV-2 exposure and HSV-2 DNA
shedding was determined by measuring the presence of HSV-2 UL30 DNA by PCR. Each sample’s integrity was verified by amplifying the GAPDH
gene. The percentage of samples positive for HSV-2 UL30 DNA at the indicated time points is shown relative to the primary exposure to HSV-2. The
numbers above the bars indicate the number of animals tested at each time point. (B) The DNA shedding is shown for each animal, where the
numbers above the bars denote the number of times that animal was sampled during the study. (C,D) 3–6 (Biopsy 1) or 9–12 (Biopsy 2) months after
co-challenge vaginal and cervical biopsies were taken from 8 animals and vaginal swabs were collected 4 hours, 1, 3 and 7 days later. (C)
Representative gels resolving the amplified 146 bp HSV-2 UL30 gene and the 226 bp GAPDH gene control are shown for a set of samples from one
animal. (D) The percentage of HSV-2 DNA positive animals for the indicated samples are provided (n=8 for each biopsy).
doi:10.1371/journal.pone.0008060.g001
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HSV-2 challenge. This contrasts with the ,46% SHIV-RT
infection frequency seen in 1X Depo-Provera-treated naı ¨ve
animals [28]. Consequently, it was impossible to elucidate if
HSV-2 infection impacted the transmission frequency of SHIV-
RT. Although Depo-Provera thins the cervicovaginal epithelium
to increase permissivity to viral infection to reproducible levels, it is
also immunosuppressive [40,41]. This is likely exacerbated when 2
doses are given within a relatively short 3 month period. Thus,
additional animals were Depo-Provera treated 4–7 months after
the initial vaginal HSV-2 challenge, before being co-challenged
(Fig. S1). In addition, animals that had been originally challenged
with HSV-2 via the rectal route (and were, therefore, not
previously Depo-Provera-treated) were Depo-Provera-treated
and co-challenged with HSV-2 and SHIV-RT (Fig. S1). Such
HSV-2-challenged animals receiving only a single Depo-Provera
treatment in the 3 month period exhibited significantly increased
susceptibility to SHIV-RT infection compared to naı ¨ve animals
(Fig. 2A, 1X Depo); 100% SHIV-RT infection in the HSV-2
group (6 of 6 animals) vs ,46% SHIV-RT infection in the naı ¨ve
group (6 of 13 animals), when challenged with 10
3 TCID50 of
SHIV-RT (Fig. 2A) (P,0.05). This was similar in animals
challenged with the lower 200 TCID50 dose of SHIV-RT
(Fig. 2A, 1X Depo); ,37% SHIV-RT infection in the HSV-2
group (3 of 8 animals) vs 0% SHIV-RT infection in the naı ¨ve
group (0 of 5 animals; not statistically significant). Despite the
increased frequency of infection in the 1X Depo-Provera-treated
HSV-2 exposed animals, comparable levels and kinetics of plasma
viremia were observed in all infected animals, with peak levels
occurring typically 2 weeks after challenge (Fig. 2B). Interestingly,
infected animals that were treated twice, vs single treatment with
Depo-Provera, maintained higher SHIV-RT viremic set-points for
6 months post-infection, although peak viral loads were compa-
rable (Fig. 2B).
HSV-2 Exposure Elicits Acute Innate and Long Lasting
Adaptive Responses
During the first days of primary HSV-2 exposure, acute
responses to HSV-2 were observed in the vaginal swabs of all
monkeys (Fig. 3A). Production of IL1b, IL2, IL4, IL12, IFNc,
TNFa, and CCL3 peaked 1–2 days post challenge, while CCL3
and CCL5 levels increased again around 14 days after challenge.
CXCL8 levels initially decreased going back to pre-challenge
levels within 14 days (data not shown).
Local cytokine and chemokine responses were further moni-
tored over the first 6 weeks of HSV-2/SHIV-RT co-challenge and
compared to the responses seen in naı ¨ve animals infected solely
with SHIV-RT. Elevated cytokine (IL2, IL4, IL12p40, and IFNc)
and chemokine (CCL2, CCL3, and CCL5) levels were detected
within 1 week of SHIV-RT infection of naı ¨ve macaques, but these
were often lower or delayed in the HSV-2/SHIV-RT co-infected
animals (Fig. 3B; although none of these differences reached
statistical significance. Note the smaller scales for the cytokines in
panels A and B.) Levels tended to normalize to baseline values
within 3–4 weeks of infection in all animals, with IL2, IL4,
IL12p40, IFNc, and CCL3 increasing again after 6 weeks of
SHIV-RT infection of the naı ¨ve animals (not statistically
significant). After the initial decrease in CXCL8 levels in both
groups of animals, the levels normalized to pre-infection levels.
The ELISPOT assay, measuring IFNc-secreting antigen-
specific T cell responses, was used to assess adaptive cellular
responses to both HSV-2 and SHIV-RT infection over time.
HSV-2 specific cellular responses were not seen prior to HSV-2
exposure (,2 SFC/2610
5 cells, averaged from 3 baseline bleeds
prior to challenge; not shown). Minimal HSV-2-specific responses
were seen after primary HSV-2 challenge in the short time prior to
co-exposure to HSV-2 and SHIV-RT (sampled on 1, 2, 3, 4, 6,
and 11 weeks post challenge; week 11 post primary HSV-2
challenge is the week 0 in Fig. 4A, left panel). After co-challenge
these responses increased (Fig. 4A, left panel; HSV-2-specific
responses were not monitored in SHIV-RT-infected animals).
Comparable numbers of SIV-specific IFNc-producing cells were
found in the PBMCs of SHIV-RT-infected and HSV-2/SHIV-
RT co-infected animals (Fig. 4A, right panel). SIV-specific T cell
responses persisted over time in both groups, with comparable
responses being detected in the blood and lymph nodes (,10
months post SHIV-RT challenge; Fig. 4B).
To evaluate if depletion of CD8
+ lymphocytes would affect
HSV-2-specific viral and immune parameters in HSV-2/SHIV-
RT co-infected macaques, we depleted HSV-2/SHIV-RT co-
infected and SHIV-RT-infected (,6 months after SHIV-RT
exposure for both groups) monkeys of CD8
+ cells [29].
CD8
+ T cells were depleted from the peripheral blood within 3
days of Ab administration and started to rebound at day 21 (Fig.
S3A). In all animals the plasma SHIV-RT levels increased within
3–7 days of anti-CD8 mAb treatment (2167.1 and 16614.2 mean
fold increase at day 3 and 34.3614 and 1168.1 mean fold
increase at day 7 for HSV-2/SHIV-RT co-infected and SHIV-
RT-infected animals, respectively) and returned to pre-depletion
Figure 2. HSV-2-exposed macaques are more susceptible to vaginal SHIV-RT infection. (A) Naı ¨ve or HSV-2-exposed macaques were
challenged with the indicated TCID50 of SHIV-RT or SHIV-RT and HSV-2 (respectively), after receiving one (1X) or two (2X) doses of Depo-Provera (Fig.
S1) and the percentage of SHIV-RT-infected animals is shown (numbers above the bars indicate animal numbers per group). The asterisk marks the
statistically significant (P,0.05) difference between 1X Depo-Provera-treated naı ¨ve vs HSV-2-infected animals receiving 10
3 TCID50 of SHIV-RT. (B)
Plasma viremia (mean RNA copies/ml6SEM) in SHIV-RT-infected naı ¨ve (left panel) and HSV-2-exposed (right panel) macaques post challenge with 10
3
TCID50 after 2 doses of Depo (10
3 2X Depo - Naı ¨ve n=4; HSV-2 n=2) or after 1 dose of Depo (10
3 1X Depo - Naı ¨ve n=6; HSV-2 n=6) and 200 TCID50
after 1 dose of Depo (200 1X Depo - HSV-2 n=3).
doi:10.1371/journal.pone.0008060.g002
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T-cell responses were monitored over time by IFN-c ELISPOT and the data are expressed as the mean (6SEM) HSV-2- (left panel) or SIV-specific (right
panel) spot-forming cells (SFC) per 2610
5 PBMCs. (HSV-2/SHIV-RT co-infected closed symbols, n=8; SHIV-RT-infected open symbols, n=10). (B) The
mean (6SEM) numbers of SIV-specific SFC per 2610
5 cells are plotted for the blood (left panel) and for the LNs (right panel) collected upon
euthanization of HSV-2/SHIV-RT co-infected animals (n=8, 10–13 months post co-challenge) vs animals only infected with SHIV-RT (n=3, 10–12
months post challenge).
doi:10.1371/journal.pone.0008060.g004
Figure 3. Local immune responses following HSV-2 infection. (A) Naı ¨ve Depo-Provera-treated monkeys (n=12) were challenged i.vag. with
2610
8 pfu HSV-2. Cytokine/chemokine levels were measured in the vaginal swabs during the first days after challenge using the 14-plex Luminex
assay. The mean concentration ng/ml (6SEM) of each factor is shown. (B) Vaginal swabs were collected after HSV-2/SHIV-RT co-challenge of HSV-2-
infected animals (n=5, closed symbols) or SHIV-RT challenge of naı ¨ve animals (n=6, open symbols). The cytokine/chemokine levels (mean6SEM ng/
ml) were measured by Luminex assay on a weekly basis.
doi:10.1371/journal.pone.0008060.g003
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+ cells began to normalize (Fig. S3B).
HSV-2 DNA shedding was not enhanced during CD8
+ cell
depletion and in fact tended to decrease over time, with an average
of 35.7% shedding in the 8 weeks following the treatment (each of
the 7 animals was positive at least once in the 10 samples taken per
animal over this period), without any obvious lesions developing.
Since HSV-2 and HIV/SIV are known to affect DC biology
[35,42–44], CD80 and CD86 levels were monitored on blood
PDCs (Lineage
-HLA-DR
+CD123
+ cells) and MDCs (within the
CD123
2 fraction for the Lineage
2HLA-DR
+ cells) [33,35] during
CD8
+ cell depletion (Fig. S3C). Starting levels of CD80/CD86
expression were comparable between the groups. CD80/CD86
expression increased during CD8
+ cell depletion (days 7–14), but
this only reached statistical significance (peak levels relative to the
pre-treatment baseline levels) for CD80 expression by MDCs in
co-infected animals after 7 days (P,0.002, Fig. S3C, lower left
panel), and for CD80 expression by PDCs in co-infected animals
after 14 days (P,0.002) (Fig. S3C, lower right panel). CD80/
CD86 expression decreased from peak between days 14 and 21 of
treatment (P,0.002 for CD80/CD86 expression on both MDCs
and PDCs in co-infected animals; peak vs day 21 values). Although
the trends were similar, no significant differences were observed in
CD80/CD86 expression in SHIV-RT-infected animals, likely due
to the limited number of animals in this group. CD80/CD86
expression began increasing towards baseline levels from day 42.
At day 7 of treatment, the elevated CD80 expression by PDCs
(Fig. S3C, lower right panel) in SHIV-RT-infected animals was
significantly greater than that in co-infected macaques (P,0.03,
Fig. S3C, lower right panel). In addition, HSV-2/SHIV-RT co-
infected animals exhibited an approximately one-week delay in
rebound toward baseline levels. Coincident with this delay, at day
42, CD80 and CD86 expression on MDCs, and CD86 on PDCs
were significantly lower in co-infected vs SHIV-RT-infected
animals (P,0.05). MDC and PDC percentages did not change
after CD8
+ cell depletion (data not shown). HSV-2- and SIV-
specific IFNc responses by PBMCs decreased during CD8
+ cell
depletion (Fig. S3D, peak effect after 7 days). HSV-2-specific
responses were reduced ,2 fold in the HSV-2/SHIV-RT co-
infected animals at day 7 after CD8
+ cell depletion (Fig. S3D, left
panel). While SIV-specific IFNc responses decreased ,2 fold in
the SHIV-RT-infected animals, there was a ,9 fold reduction in
HSV-2/SHIV-RT co-infected animals at day 7 (Fig. S3D, right
panel). However, the difference between the two groups did not
reach statistical significance.
Antigen-specific T cell responses were examined in more detail
by ICS to more accurately dissect the involvement of CD4
+ and
CD8
+ T cells (,12 months post SHIV-RT or HSV-2/SHIV-RT
challenge). In HSV-2/SHIV-RT co-infected animals both HSV-2-
and SIV-specific CD4
+ and CD8
+ T cells were found to produce
IFNc, IL2, or TNFa alone, with relatively fewer cells typically
producing two or more of these cytokines (Fig. 5A). HSV-2-specific
CD8
+ T cell responses were typically stronger than the CD4
+ T cell
responses, but this did not reach statistical significance. To
determine whether HSV-2 infection affected SIV-specific T cell
responses in SHIV-RT-infected animals, we compared PBMCs
from both groups using ELISPOT and ICS. By ELISPOT assay,
Figure 5. HSV-2-specific CD4
+ and CD8
+ T cell responses are detected in HSV-2/SHIV-RT co-infected animals. (A) HSV-2- (left panel) and
SIV-specific (right panel) CD4
+ (black bars) and CD8
+ (grey bars) T cells were detected in the blood of co-infected animals (,12 months after co-
challenge, n=8) by multicolor ICS. The percent positive cells producing the indicated cytokines in response to each antigen (mean6SEM; single vs
double or triple producers) are shown after subtracting the respective background signals of the IgG and no-virus MV controls. (B,C) SIV-specific T-cell
responses were compared between SHIV-RT-infected (n=5) and HSV-2/SHIV-RT co-infected (n=5) animals ,12 months post co-challenge, by IFNc
ELISPOT (B) or ICS (C). (B) The mean (6SEM) SIV-specific SFC/2610
5 cells are shown. (C) The percent positive cells producing the indicated cytokines in
response to SIV (mean6SEM; single vs double or triple producers) are shown after subtracting the respective background signals of the IgG and no-
virus MV control. (D) Approximately 12 months after challenge with SHIV-RT or co-challenge with HSV-2/SHIV-RT, the fold decreases in CD4 counts
(mean6SEM, relative to pre-exposure levels) (left axis, stars) and plasma viral loads (mean RNA copies/ml6SEM, right axis, circles) are shown (n=5 for
both).
doi:10.1371/journal.pone.0008060.g005
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HSV-2/SHIV-RT-co-infected animals (Fig. 5B), as seen at the
earlier time points (Fig. 4A). Additionally, there was no significant
difference in the SIV-specific cytokine secretion profiles from both
CD4
+ and CD8
+ T cells between SHIV-RT-infected vs co-infected
animals (Fig. 5C). Within each infection group, CD4
+ T cells
predominantly expressed cytokines, while the CD8
+ T cell response
was lower than 0.05% (at this time point; Fig.5C). Taken together,
these results are consistent with there being no difference in the
decrease in CD4 counts (relative to pre-infection) and the levels of
plasmaSHIV-RT RNAinHSV-2/SHIV-RTco-infected vs SHIV-
RT infected animals at this time point (Fig. 5D).
SIV-specific Ab responses were detected in all SHIV-RT-
infected and in 85% of the HSV-2/SHIV-RT co-infected animals
(Tables 1 and 2). Low-level HSV-2-specific Ab responses were
detected in 75% of the HSV-2/SHIV-RT co-infected animals
(mean 2.3260.54 fold increase in OD above the pre-challenge
values in 9 of 12 animals tested). Two of the HSV-2 Ab negative
animals were positive for HSV-2 DNA shedding (GF24 and
GF22), while animal GF19 was both Ab and HSV-2 DNA
negative.
PC-817 Protects against Enhanced Vaginal SHIV-RT
Infection in HSV-2-Exposed Macaques
Having demonstrated HSV-2 infection of macaques and that
HSV-2 exposure significantly enhanced the frequency of SHIV-
RT infection in this model, we wanted to utilize this system to
carry out the first test of a lead microbicide gel comprising the
NNRTI MIV-150 in Carraguard (PC-817) for its ability to prevent
SHIV-RT infection under these more rigorous conditions. PC-817
was tested for its ability to prevent vaginal SHIV-RT infection
when applied 30 minutes or 24 hours prior to co-challenge of
HSV-2-exposed animals with HSV-2 and SHIV-RT (Fig. 6) vs a
placebo control gel, MC.
Just as in naı ¨ve animals challenged with SHIV-RT [28]
(unpublished observations), PC-817 administered 30 minutes prior
to exposure completely prevented SHIV-RT infection in HSV-2
infected macaques (Fig. 6A, middle panel) despite their enhanced
susceptibility to infection (Fig. 2). However, PC-817 no longer
protected when applied 24 hours before the 10
3 TCID50 inoculum
(Fig. 6A, right panel). The mean viral loads of the infected animals
were comparable in the animals treated with MC or pretreated
with PC-817 24 hours before challenge (Fig. 6B). Pre-treatment
Figure 6. PC-817 protects against vaginal SHIV-RT infection when given just prior to HSV-2/SHIV-RT co-challenge. (A) PC-817 or MC
was applied 30 minutes (30 min) and 24 hours (24 h) prior to challenge of HSV-2-exposed animals with 10
3 TCID50 SHIV-RT and 2610
8 pfu HSV-2.
Plasma viral loads are shown for control animals (MC) (n=5) in the left panel, for animals that received PC-817 30 min before the challenge (n=8) in
the middle panel, and for animals that received PC-817 24 h prior to challenge (n=5) in the right panel. (B) Mean (6SEM) plasma viremia of the 3
treatment groups from (A) are shown. (C) PC-817 or MC was applied 24 h prior to challenge with 200 TCID50 of SHIV-RT and 2610
8 pfu HSV-2. The
plasma viral loads are provided for the MC control animals (n=2) in the left panel and the PC-817-treated animals (n=6) in the right panel. (D) Data
from panels (A) and (C) are summarized to show the frequency of infection for the differently treated groups. The asterisk highlights the statistically
significant (P,0.001) difference in the numbers of infected animals receiving PC-817 (vs MC) 30 min prior to challenge with 10
3 TCID50 of SHIV-RT and
HSV-2.
doi:10.1371/journal.pone.0008060.g006
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effective when the HSV-2-infected animals were co-challenged
with the lower 200 TCID50 inoculum of SHIV-RT and HSV-2
(Fig. 6C, 50% infection in MC vs 16.7% infection in PC-817-
treated animals; not statistically significant, likely due to the small
number of animals in the MC group). As expected, all plasma
viremia positive animals carried infectious virus in their blood cells
and most developed both SIV-specific IFNc-producing cells and
Abs (Table 2). The percentage of infected animals in each of the
treatment groups is summarized in Figure 6 D. The potent effect
of PC-817, when administered just prior to exposure, in
preventing SHIV-RT infection in HSV-2-infected animals despite
their enhanced susceptibility to SHIV-RT infection is clear
(P,0.001).
Discussion
HSV-2 enhances HIV acquisition and transmission during
symptomatic and asymptomatic stages of infection [3,4,18]. The
exactmechanism via whichHSV-2 does thisremainsunknown, due
to the difficulties in studying human infections and the lack of an
animal model to study HSV-2/immunodeficiency virus co-infection
[45,46]. However, recent studies have revealed that, even after anti-
HSV-2 therapy, recruited HIV receptor-positive T cells and DCs
persist at sites of HSV-2 reaction, thereby possibly contributing to
continued HIV replication and spread [21]. Herein,we describe the
first relevant primate HSV-2/SHIV-RT co-infection model that
can be used to closely dissect the mechanism by which HSV-2
enhances immunodeficiency virus spread. Moreover, this model
allows the assessment of promising anti-viral strategies for their
ability to prevent immunodeficiency virus infection under these
more physiologically demanding conditions. The rationale for first
exposing animals to HSV-2 and then co-challenging them with
HSV-2 and SHIV-RT was to give us the best chance of getting
HSV-2 infection (with the limited numbers of animals available for
this study), since this is something that has not documented
previously. While HSV-2 infected humans might be more likely
exposed to HIV alone, it is not impossible that someone infected
with HIV and HSV-2 could spread both viruses (or at least HIV) to
another individual (who might already by HSV-2 positive) during
one encounter. This study was carried out to provide the first proof
that HSV-2 can infect macaques vaginally and that HSV-2
exposure enhances SHIV-RT infection. Future studies are now
justified to explore sequential exposure vs co-exposure with both
viruses, in order to further dissect how HSV-2 alters the
susceptibility to HIV infection. This work provides the first
important step towards that goal.
Although HSV-2 infection of humans can be asymptomatic
[18,47,48], viral shedding occurs frequently, with the median
duration of a shedding episode estimated to be between 6–48 h
[8,49]. More recent evidence further supported that shedding and
lesions are rapidly cleared and typically asymptomatic [12]. We
observed frequent shedding in HSV-2-challenged macaques for
approximately 2 years, but this might even be an underestimate if
the short window of shedding was missed in our sampling
schedules. Increased HSV-2 shedding was detected after biopsying
the cervical and vaginal tissues (especially earlier in infection),
despite there being little evidence of DNA positivity at the time of
biopsy, suggesting that the trauma associated with the biopsies
reactivated shedding. HSV-2 detection was reportedly higher in
recently infected compared to chronically infected people [50].
Since all HSV-2-challenged animals were ultimately co-challenged
with HSV-2 and SHIV-RT we were unable to accurately
determine if HSV-2 shedding significantly decreased over time
in macaques, although there was less reactivation upon biopsying
at the later time points.
HSV-2 vaginal challenge in macaques induced acute local
cytokine and chemokine responses, as well as adaptive T and B cell
responses. Because we were unable to include controls of animals
exposed to UV-inactivated HSV-2, we cannot rule out that the
local innate responses were not simply due to a ligand effect of cells
responding to the virus particles. However, in mice vaginally
challenged with HSV-2, early production of chemokines such as
CCL2 and CCL5 in vaginal mucosa has been reported [51], as
well as massive recruitment of B cells from the vaginal mucosa to
the lymph nodes [52]. Type I IFNs, b-chemokines, IL1, IL6 and
IL12 are also released in human herpetic lesions [7]. Similar
cytokine and chemokine responses detected in the first days after
vaginal HSV-2 exposure of macaques likely contribute to the
recruitment of T cells, macrophages, and DCs that are important
in controlling infection [8,9,21]. The somewhat delayed local IL2
and CCL5 and lower CCL3 responses observed after co-challenge
of HSV-2-infected macaques compared to those detected after
SHIV-RT infection of naı ¨ve animals, suggest that HSV-2
impaired the responses to SHIV-RT. Not surprisingly, this did
not ultimately inhibit the development of SIV-specific T or B cell
responses, since these typically develop in most immunodeficiency
virus infected animals. This contrasts with a recent report that co-
infection with HSV-2 and HIV was associated with a weaker HIV-
specific T cell responses [53].
CD8
+ T cells play a pivotal role in controlling HSV-2 infection
and reactivation locally in the peripheral mucosa [8,21] and in
controlling SIV infection [54]. As expected, SIV RNA levels
increased and antigen-specific T cell responses decreased upon
CD8
+ cell depletion, indicating the involvement of CD8
+ cells in
the HSV-2- and SIV-specific responses of macaques. HSV-2-
specific CD4
+ and CD8
+ T cells producing TNFa, IL2, or IFN c
were also identified in the blood of co-infected animals by ICS,
with the CD8
+ T cell responses being greater. T cells producing
combinations of two or all of these factors were less frequent.
Despite the depletion of CD8
+ cells, there was no increase in HSV-
2 shedding in the vaginal swabs. This might be explained by sub-
optimal CD8
+ cell depletion in genital tissue, since we did not
monitor CD8
+ cells locally.
The changes in CD80/CD86 expression by DCs during
CD8
+ cell depletion were similar in SHIV-RT-infected and
HSV-2/SHIV-RT co-infected animals, suggesting that the DC
activation was likely due to SHIV-RT-driven activation when
the plasma virus loads increased with CD8
+ cell depletion. SIV
and HIV activate PDCs, with at least some bystander activation
of MDCs [33,42], but this activation is often suboptimal for full
immune stimulation [35]. The rebound of CD80/CD86
expression was delayed in the HSV-2/SHIV-RT co-infected
animals, although this was only evident at one time point. We
showed previously that HSV-2-infected monocyte-derived DCs
were defective in their ability to stimulate SIV-specific T cell
responses in vitro [17]. Reduced CD83 expression by HSV-2-
exposed DCs has been associated with lessened immunostimu-
latory function [16,55,56], but CD83 was not monitored in our
study. However, we did not observe lower SIV-specific
responses in the blood of the co-infected animals, which might
have been more apparent at local infection sites or sites of
reactivation where DCs would be more likely to become
infected by HSV-2.
HSV-2 exposure increased the monkeys’ susceptibility to
vaginal SHIV-RT infection, supporting the observations of
increased HIV infection in HSV-2 seropositive people, with or
without detectable herpetic lesions [3,4]. Lesions were not
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effect of HSV-2 exposure in the co-challenge cannot be
excluded based on the way these experiments were performed.
W h i l ew ec a n n o tr u l eo u tt h ec o n t r i b u t i o no fr e c r u i t e dD C sa n d
T cells to microlesions not visible by colposcopy [21], it is
possible that the immunosuppressive activities of HSV-2
infection also contribute to the animals’ increase susceptibility
to SHIV-RT infection. Depo-Provera not only thins the vaginal
epithelium rendering animals more uniformly susceptible to
vaginal challenge [40], it has also been shown to immunosup-
press animals, undermining the protective capacity of nef-
defective SIV [41]. The fact that the double Depo-Provera
treatment (within a 3 month period) somewhat mirrored the
HSV-2 effect in naı ¨ve animals, supports the idea that
immunosuppression can contribute to immunodeficiency virus
infection. Despite the increased frequency of immunodeficiency
infection in HSV-2-infected macaques, we did not observe any
significant changes in the SHIV-RT plasma viral loads, as has
been described in humans (0.33–1 log more HIV in HSV-2-
infected people) [2].
Using this HSV-2/SHIV-RT model in which the SHIV-RT
infection frequency is enhanced, we tested whether a promising
new generation microbicide (using Carraguard as the delivery
vehicle) was still able to protect against SHIV-RT infection as it
did in naı ¨ve animals [28]. Although Carraguard did not
demonstrate efficacy against HIV infection in women in a recent
efficacy study, it was found to be safe and acceptable [57]. As
such, new generation formulations are being explored, where
C a r r a g u a r ds e r v e sa st h ev e h i c l et o introduce other anti-viral
components. Herein, we tested Carraguard combined with MIV-
150 (a combination formulation designated PC-817); in vitro the
two components have been shown to have additive activities
against HIV [28,58]. Just as we observed in naı ¨ve macaques [28]
(unpublished observations), PC-817 completely prevented SHIV-
RT infection when applied just prior to challenge, but exhibited
little or no activity when applied 24 hours prior to challenge.
This has important implications for the advancement of coitally
independent strategies thatfunction innaı ¨ve and HSV-2-infected
settings, and studies examining different timing strategies, as well
as repeated gel applications are ongoing.
This represents the first report demonstrating vaginal HSV-2
infection of non-human primates and that macaques exposed to
HSV-2 are more susceptible to immunodeficiency virus infec-
tion, thereby mimicking human biology. We also verified how
this model could be used to test promising microbicide
candidates. We established an animal model that could be
critical to elucidate how HSV-2 facilitates HIV spread and to
more rigorously test the efficacy of novel preventative and/or
therapeutic approaches in the presence of other sexually
transmitted pathogens.
Supporting Information
Figure S1 Treatment and challenge regimens. Schematic
diagram to detail the Depo-Provera treatments (1X vs 2X within
3 months) and challenge schedules of macaques vaginally or
rectally exposed to HSV-2 prior to HSV-2/SHIV-RT co-
challenge, vs naı ¨ve animals challenged with SHIV-RT.
Found at: doi:10.1371/journal.pone.0008060.s001 (1.04 MB EPS)
Figure S2 PCR detection of low levels of HSV-2 DNA.
2610
6 pfu of HSV-2 was used to infect T75 flasks confluent with
Vero cells (,8.4610
6 cells). Infected Vero cells were collected
48 hours post infection (when 100% cells were rounded up from
the bottom of the culture flask). Aliquots containing 5610
6 HSV-
2-infected or uninfected Vero cells were prepared. Cell suspen-
sions were centrifuged at 1500 rpm for 5 minutes at room
temperature, the supernatant removed, and dry cell pellets stored
at -80uC until DNA extraction. DNA was extracted using the
QIAamp DNA blood Mini Kit (QIAGEN, Valencia, CA)
according to manufacturer’s instructions, into 100 ml of elution
buffer. DNA from 10-fold dilutions of HSV-2 infected Vero cells (5
down to 0.00005 infected cells) was diluted on a background of
DNA from 45,000 uninfected Vero cells. HSV-2 UL30 DNA was
amplified by nested PCR on 6 replicates for each dilution.
GAPDH signals were detected in all samples (not shown). Gels
representative of at least 3 repeat experiments are shown.
Found at: doi:10.1371/journal.pone.0008060.s002 (0.91 MB EPS)
Figure S3 Impact of CD8
+ cell depletion on HSV-2/SHIV-RT
and SHIV-RT-infected animals. Blood was sampled before,
during, and after CD8
+ cell depletion of 2 SHIV-RT-infected
(open symbols) and 7 HSV-2/SHIV-RT co-infected (closed
symbols) animals; CD8
+ cell depletion was initiated ,6 months
post co-challenge with HSV-2/SHIV-RT or challenge with
SHIV-RT. Results are shown relative to the days post treatment
with the anti-CD8 mAb. (A) The CD8
+ T cell TruCount results
(numbers per ml of blood) are shown for the individual animals
over time relative to the commencement of the Ab treatment. (B)
The levels of SIV gag RNA were measured over time and the
RNA copies/ml in plasma are shown for each animal. (C) Co-
stimulatory molecule expression was measured on CD123
2
MDCs and CD123
+ PDCs within the Lineage
2HLA-DR
+ cell
population obtained from PBMCs. Mean fluorescence intensities
(MFIs, 6SEM) of CD86 (upper panels) and CD80 (lower panels)
expression by CD123
2 (CD123-) and CD123
+ (CD123+) cells are
shown over time. Asterisks indicate statistically significant
differences between the HSV-2/SHIV-RT co-infected vs SHIV-
RT-infected animals at specific time points. (D) Since the
magnitudes of the responses varied significantly between animals,
the fold reduction in the HSV-2- and SIV-specific IFNc release
was calculated by dividing the mean numbers of SFCs at day 0 by
the mean numbers of SFCs at day 7 or day 14 of anti-CD8 Ab
treatment for the respective responses. The mean fold reductions
(6SEM) are shown for 7 HSV-2/SHIV-RT co-infected and 2
SHIV-RT-infected animals. Negligible HSV-specific responses in
SHIV-RT-infected animals remained unchanged as expected (fold
,1).
Found at: doi:10.1371/journal.pone.0008060.s003 (3.26 MB EPS)
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